We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
(-16%)
Cap. Flow
+$98.4M
Cap. Flow
% of AUM
8.63%
Top 10 Holdings %
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
4.1
quarters
Top 20 Avg Time Held Equity + Options
4.2
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
4.1
quarters
Top 20 Avg Time Held Equity only
4.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$27.8M |
| 2 |
Humana
HUM
|
+$19.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$15.3M |
| 4 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$13.2M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$68.4M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$12.9M |
| 3 |
Baxter International
BAX
|
+$10.1M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$8.54M |
| 5 |
NEVRO CORP.
NVRO
|
+$8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.87% |
| 2 | Miscellaneous | 6.35% |
| 3 | Consumer Staples | 0.6% |
| 4 | Consumer Discretionary | 0.11% |
| 5 | Industrials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Eledon Pharmaceuticals
ELDN
$190M
| $2.72M | 0.24% |
2,996
| – | – |
2014 Q3
6 quarters
|
|
|
CEMP
77
DELISTED
Cempra, Inc.
CEMP
| $2.63M | 0.23% |
+150,000
| New | +$2.72M |
2016 Q1
0 quarters
|
|
78
Ardelyx
ARDX
$806M
| $2.46M | 0.22% |
315,955
| – | – |
2014 Q3
6 quarters
|
|
79
Wave Life Sciences
WVE
$619M
| $2.44M | 0.21% |
+176,000
| New | +$2.46M |
2016 Q1
0 quarters
|
|
80
DELISTED
Kineta, Inc. Common Stock
KA
| $2.41M | 0.21% |
+1,786
| New | +$1.97M |
2016 Q1
0 quarters
|
|
81
Corbus Pharmaceuticals
CRBP
$92.5M
| $2.26M | 0.2% |
41,667
| – | – |
2015 Q2
3 quarters
|
|
82
DELISTED
Regulus Therapeutics
RGLS
| $2.26M | 0.2% |
+2,712
| New | +$2.16M |
2016 Q1
0 quarters
|
|
83
United Therapeutics
UTHR
$23.3B
| $2.23M | 0.2% |
+20,000
| New | +$2.53M |
2016 Q1
0 quarters
|
|
84
Protara Therapeutics
TARA
$155M
| $2.13M | 0.19% |
6,875
| – | – |
2014 Q4
5 quarters
|
|
|
MGCD
85
DELISTED
MGC Diagnostics Corporation
MGCD
| $2.04M | 0.18% |
336,287
| – | – |
2013 Q2
11 quarters
|
|
86
DexCom
DXCM
$32.1B
| $1.8M | 0.16% |
+105,896
| New | +$1.77M |
2016 Q1
0 quarters
|
|
|
EIGR
87
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $1.76M | 0.15% |
+3,497
| New | +$1.74M |
2016 Q1
0 quarters
|
|
|
PETX
88
DELISTED
Aratana Therapeutics, Inc.
PETX
| $1.61M | 0.14% |
+291,800
| New | +$1.1M |
2016 Q1
0 quarters
|
|
|
CBPO
89
DELISTED
China Biologic Products Holdings, Inc.
CBPO
| $1.6M | 0.14% |
+14,000
| New | +$1.64M |
2016 Q1
0 quarters
|
|
|
ADYX
90
DELISTED
Adynxx Inc
ADYX
| $1.57M | 0.14% |
32,033
| – | – |
2014 Q4
5 quarters
|
|
91
Xenon Pharmaceuticals
XENE
$3.33B
| $1.44M | 0.13% |
205,800
| – | – |
2014 Q4
5 quarters
|
|
92
Champions Oncology
CSBR
$68.2M
| $1.36M | 0.12% |
372,597
| – | – |
2015 Q3
2 quarters
|
|
|
DSCI
93
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $1.34M | 0.12% |
432,884
+30,000
| +7% | +$100K |
2014 Q1
8 quarters
|
|
|
NVTA
94
DELISTED
Invitae Corporation
NVTA
| $1.21M | 0.11% |
118,366
-25,000
| -17% | -$199K |
2015 Q1
4 quarters
|
|
|
AGRX
95
DELISTED
Agile Therapeutics
AGRX
| $1.09M | 0.1% |
+88
| New | +$1.14M |
2016 Q1
0 quarters
|
|
|
NEOS
96
DELISTED
Neos Therapeutics, Inc
NEOS
| $1.08M | 0.09% |
100,000
-42,603
| -30% | -$449K |
2015 Q3
2 quarters
|
|
97
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $1.07M | 0.09% |
+26,667
| New | +$980K |
2016 Q1
0 quarters
|
|
98
DELISTED
iPath S&P 500 VIX Short-Term Futures ETN due 1/30/2019
VXX
| $1.06M | 0.09% |
+3,750
| New | +$1.41M |
2016 Q1
0 quarters
|
|
99
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
| $1.03M | 0.09% |
1,259,636
| – | – |
2015 Q2
3 quarters
|
|
|
GWPH
100
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $946K | 0.08% |
+13,109
| New | +$719K |
2016 Q1
0 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2016 Portfolio in Review
As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $98.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $12.9M trimmed.
- Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
- Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $12.9M.
- Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
- Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
- Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
- Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.
Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.